For income hunters AstraZeneca (LSE: AZN) may not be the most obvious stock candidate, the double whammy of hefty exclusivity losses and vast capital demand of drug development weighing heavily on the balance sheet.
Clearly, not all stocks pay generous dividends. This can be because it is more logical for them to reinvest in the business due to a relatively high growth rate, or because they are experiencing a challenging period.
AstraZeneca plc logo Research analysts at Jefferies Group lowered their price target on shares of AstraZeneca plc (LON:AZN) from GBX 5,800 ($91.24) to GBX 5,600 ($88.09) in a report released on Thursday.
Today I am looking at why I would - or would not - invest in these three FTSE-listed businesses. AstraZeneca. Another week, another rush to the exits at AstraZeneca (LSE: AZN) (NYSE: AZN.US) as investors fret over yet more bad news on the competition ...